ALNYLAM PHARMACEUTICALS, INC. Current Federal Tax Expense (Benefit)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Current Federal Tax Expense (Benefit) of $1.60 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2025-02-13
- ALNYLAM PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2024 was $1.60M, a 60.22% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2023 was $4.02M.
- ALNYLAM PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ALNYLAM PHARMACEUTICALS, INC. current federal tax expense (benefit) for fiscal 2021 was $293.00K, a 380.33% increase from fiscal 2020.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2024-12-31 | $1.60M 10-K · filed 2025-02-13 |
| 2023-12-31 | $4.02M 10-K · filed 2025-02-13 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-13 |
| 2021-12-31 | $293.00K 10-K · filed 2024-02-15 |
| 2020-12-31 | $61.00K 10-K · filed 2023-02-23 |
| 2019-12-31 | -$394.00K 10-K · filed 2022-02-10 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 |
| 2013-12-31 | $34.00K 10-K · filed 2016-02-12 |
| 2012-12-31 | $52.00K 10-K · filed 2015-02-13 |
| 2011-12-31 | $52.00K 10-K · filed 2014-02-20 |
| 2010-12-31 | -$9.93M 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |